Today Stories

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, has been named to the Fortune® World's Most Admired Companies™ list for the seventh consecutive year. For the third year in a row IQVIA earned the first-place ranking within the Health Care: Pharmacy and Other Services category. The company also ranked number one in six categories for quality of management, people management, innovation, quality of products and services, global competitiveness, and use of corporate assets. Fortune® World's Most Admired Companies™ is the definitive report card on corporate reputation. Since 1997, Fortune® has identified, selected, and ranked the World’s Most Admi…

The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes™” aims to enhance awareness of and access to cancer screening, clinical trials and support in medically underrepresented communities across the United States ATLANTA & NEW YORK--(BUSINESS WIRE)-- The American Cancer Society (ACS) and Pfizer Inc. (NYE: PFE) today announced the launch of “Change the Odds: Uniting to Improve Cancer Outcomes™,” a three-year initiative to bridge the gap in cancer care disparities. Through $15 million in funding from Pfizer, the initiative aims to improve health outcomes in medically underrepresented communities across the United States by enhancing awareness of and access to cancer screenings, clinical trial opportunities, and patient support and comprehensive navigation. “Change the Odds”…

Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses Paris, February 5, 2024. Sanofi today launches ‘Cancer & Work: Acting Together’, a global program to support Sanofi employees whose lives are impacted by cancer and other critical illnesses. This program covers all Sanofi employees in the world if they are diagnosed with cancer or critical illnesses*. It provides social, emotional and financial support and secures the job, salary and benefits of any employee for up to twelve months, no matter the role or geographical location. Natalie BickfordChief People Officer, Sanofi“Many of us will face cancer one way or another in our lives. The last thing you want to be thinking about when you are di…

BURLINGTON, N.C., Feb. 1, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has once again been named to FORTUNE® magazine's list of the World's Most Admired Companies™, a recognition of the most respected and reputable companies globally. "Labcorp is honored to be included on this year's FORTUNE World's Most Admired Companies list," said Adam Schechter, chairman and CEO of Labcorp. "This recognition is a testament to the hard work and dedication of Labcorp employees who work tirelessly to help address some of the world's most important health challenges and support our mission to improve health and improve lives." The annual survey designated Labcorp as one of only five companies to attain Most Admired status in the "Health Care:…

Italian investors, NEVA SGR, LIFTT and Simon Fiduciaria, join the existing syndicate Additional investment brings the total Series B financing to £31.1 million (approx. USD $39.5 million) London, UK, 1 February 2024 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces a further extension of £9.6m (approx. USD $12.2m) to its Series B financing round. With participation from its existing syndicate, CPF managed by Sixth Element Capital, Claris Ventures, Astellas Venture Management, 3B Future Health Fund, 2investAG, and the addition of three new investors – NEVA SGR (the venture capital arm of Intesa Sanpaolo banking group), LIFTT (the venture capital focused on deep-tech chaired by Stefano Buono) and Simon Fiduciaria (the fiduciary company of Ersel Group)…

The 38th PM Society Awards will take place on Friday 15th March in London with Twist Health as the headline sponsor. They are the longest running and largest awards event in the pharma marketing and healthcare agency calendar. To view all the finalist agencies and clients, please visit the PM Society’s website. Where: JW Marriott Grosvenor House LondonWhen: Friday 15th March 2023Time: 12:00pm - 8:00pmDress code: Semi Formal The awards attract around 1000 guests, showcases the best creative work our industry has to offer and gives an opportunity for attendees to network and celebrate! Buy your tickets now and also enjoy:• An exciting digital exhibition before the awards ceremony• Networking with your colleagues, clients and teams• Three-course meal with wine• Top comedy talent  For more inf…

– New Median Turnaround Time from Leukapheresis to Product Release in U.S. Anticipated to be Reduced from 16 Days to 14 Days – – Continues to Support Kite’s Industry-Leading Overall Turnaround Time and Reliability – – Time to Treatment is a Critical Factor for CAR T-cell Therapy Patients – SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing process change resulting in a shorter manufacturing time for Yescarta® (axicabtagene ciloleucel). With this approval, Kite’s median turnaround time (TAT) in the U.S. is anticipated to be reduced from 16 days to 14 days. Median TAT is defined as time from leukapheresis, when a patient’s T cells are collected, to product release; manu…

Investment Reinforces Companies’ Conviction in TIGIT Pathway and Provides Opportunity to Accelerate the Anti-TIGIT Program Additional Equity Investment of $320M, Raising Gilead’s Ownership Stake in Arcus to 33% Amendment Provides Gilead with One Additional Seat on the Arcus Board FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share. The equity investment and collaboration amendment enable accelerated growth of the companies’ joint development programs that span multiple indications. Additionally, Johanna Mercier, Chief Commercial Officer at…

Bracknell, UK. 29th January 2023: PharmiWeb, the leading global life science news and jobs portal, is excited to unveil its new branding in line with the company’s 25th anniversary celebrations. This fresh visual identity symbolises PharmiWeb’s commitment to continuous evolution, and to creating a standout user experience for both candidates and clients, whilst still paying homage to the company’s origins. Whilst the new branding maintains the trusted blue, grey, and golden yellow colour palette that has become synonymous with PharmiWeb, new photo-based imagery has been utilised on the PharmiWeb websites to inject new life into the brand. A new ‘dot’ design has also been used to bring dynamism and vibrancy into the brand. The PharmiWeb logo remains the same, with a tagline that has been re…

If approved, AstraZeneca and Daiichi Sankyo’s Enhertu will potentially be the firstHER2-directed treatment and antibody drug conjugate to receive a tumour-agnostic indication Application based on results from DESTINY-PanTumor02 trial and supported by additional Enhertu data Submission to be reviewed under FDA Real-Time Oncology Review and Project Orbis AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumours who have received prior treatment or who have no satisfactory alternative treatment options. The sBLA is based on data from the ongoi…

– US$223 million expansion will add biologics capacity to AbbVie manufacturing network– Singapore manufacturing site to grow to more than 500 employees following expansion– Construction will commence immediately with facilities becoming operational in 2026 SINGAPORE Jan. 26, 2024 – AbbVie (NYSE: ABBV) strengthened its manufacturing capabilities by breaking ground Thursday on a new US$223 million (S$301 million) expansion of its Singapore manufacturing facility. This new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVie's global network. Located in Singapore's Tuas Biomedical Park, AbbVie's Singapore plant is a state-of-the-art small-molecule and biologics manufacturing facility serving markets worldwide. This new investment will add 24,000 liters of…

Dublin, Ireland – 24 January 2024 – ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced results from a recent industry survey of over 100 professionals engaged in obesity-related clinical research to measure industry opinions on trends within this therapeutic area. The majority of respondents believe the future of obesity therapies lies in trials that are designed to measure more than one outcome. There is much overlap between obesity and co-morbidities such as diabetes, steatosis (fatty liver), and cardiovascular disease, and in line with this, most respondents (64%) felt combination therapies would be the primary focus of future research. Furthermore, half of respondents are employing multi-indication studies…

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Mirati Therapeutics, Inc.® (“Mirati”). With the completion of the acquisition, Mirati shares have ceased trading on the NASDAQ Global Select Market and Mirati is now a wholly owned subsidiary of Bristol Myers Squibb. “The closing of the Mirati transaction is a significant milestone in our efforts to further diversify our oncology portfolio and strengthen our pipeline in the latter half of the decade and beyond,” said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb. “Mirati’s incredibly talented employees have built a strong portfolio of assets and capabilities that are highly complementary with BMS’. We welcome them and look forward t…

Sano Genetics is the only software platform tailored to running precision medicine clinical trials, leveraging AI to manage all aspects from design to patient recruitment, to genetic and other biomarker testing and patient engagement Precision medicine is a fast-growing category - today more than 30% of trials are precision-driven which is predicted to reach 80% by the end of the decade Sano Genetics is experiencing huge demand for its product, experiencing 5x growth ARR year-on-year and now serving four of the major pharmaceutical companies  New funding brings the total raised by the company to $22M to help it meet demand and further automate its processes  Cambridge, UK, 22nd January 2024: Sano Genetics, a software company accelerating precision medicine research, has raised $11.4 mill…

GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients. WALTHAM, Mass. & MONZA, Italy--(BUSINESS WIRE)-- Thermo Fisher Scientific, the world leader in serving science, has received Good Manufacturing Practice (GMP) approval from the Italian Medicines Agency (AIFA) allowing the company to manufacture RNA-based products at its Monza, Italy site. The approval and associated certification support increased accessibility to novel therapies for patients with difficult to treat conditions, marking a significant achievement within the Thermo Fisher Scientific network and for Italy as a whole. “RNA technology is being explored for a variety of modalities, including rare diseases and cancer which have limited treatment options,”…

Specialist preclinical contract research organisation (CRO) Cellomatics Biosciences has heralded the start of its next successful phase with four promotions and eight new arrivals. Dr Shailendra Singh, CEO of Cellomatics Biosciences, comments: “Capitalising on our existing strengths and internal team expertise, we intend to further consolidate our position as a specialist biology CRO by broadening and deepening our service offerings in 2024. With these new appointments and internal restructuring, we are poised to catapult ourselves to the next phase of our growth journey.” Cellomatics is building on its expanding client base which now boasts over a hundred global clients, delivering approximately 320 scientific projects across all therapeutic areas of which sixty-six projects were complete…

High scores in development and steering practices reflect how individual growth contributes to our company purpose Benefits focusing on employee wellbeing continue to stand out The Top Employers Institute awarded Boehringer Ingelheim for the fourth year in a row a “Global Top Employer”, one of 17 globally certified companies. The 2024 certification reflects the impact of the comprehensive learning and development opportunities at Boehringer. Boehringer’s employer offerings receive particularly high scores in the categories “Develop” and “Steer” pointing out a link between individual development and the company purpose of transforming lives for generations. The internal Boehringer Ingelheim University is a key element in this. It includes a state-of-the-art virtual campus where learni…

- Approximately 1,000 patients in the U.S. 12 years of age and older are now eligible for this one-time treatment - BOSTON--(BUSINESS WIRE)--Jan. 16, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy, for the treatment of transfusion-dependent beta thalassemia (TDT) in patients 12 years and older. “On the heels of the historic FDA approval of CASGEVY for sickle cell disease, it is exciting to now secure approval for TDT well ahead of the PDUFA date,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “TDT patients deserve new, potentially curative treatment options, and we look forward to bri…

Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5 Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6 Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possible Basel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection. Last year, more than 38,000 people in the EU received Tecentriq to treat different types of lung, liver, bladde…

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced a further expansion and upgrade of its plant in Koropi, Greece. With an investment of EUR 120 million, the company will increase the manufacturing capacity of new and existing medications, some of them in the late-stage development of the company’s strong innovation pipeline. Main disease areas include cardio-renal-metabolic (CRM) diseases, mental health, and pulmonary fibrosis. The expansion will create 110 additional jobs and boost medicine exports from Greece, particularly of Jardiance®, a medication used to treat type 2 diabetes, chronic (long-term) heart failure and chronic kidney disease, to the US market. Greek Prime Minister Kyriakos Mitsotakis attended the groundbreaking ceremony at the K…